

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/809,425
				Filing Date	March 26, 2004
				First Named Inventor	Mia LEVITE
				Group Art Unit	1644
				Examiner Name	JALLA, SANJOO
Sheet	2	Of	2	Attorney Docket Number	27644
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	3	Sperner-Unterweger et al. "T-Cell Subsets in Schizophrenia: A Comparison Between Drug-Naïve First Episode Patients and Chronic Schizophrenic Patients", Schizophrenia Research, 38: 61-70, 1999.			
	4	Schwartz et al. "Protective Autoimmunity: Regulation and Prospects for Vaccination After Brain and Spinal Cord Injuries", Trends in Molecular Medicine, 7(6): 252-258, 2001.			
	5	Schori et al. "T-Cell-Based Immunity Counteracts the Potential Toxicity of Glutamate in the Central Nervous System", Journal of Neuroimmunology, 119: 199-204, 2001.			
	6	Kuo et al. "The Involvement of Glutamate in Recall of the Conditioned NK Cell Response", Journal of Neuroimmunology, 118: 245-255, 2001.			
	7	Riewald et al. "Expression of Bomapin, A Novel Human Serpin, in Normal/Malignant Hematopoiesis and in the Monocytic Cell Lines THP-1 and AML-193", Blood, 91(4): 1256-1262, 1998.			
	8	Levite "Nervous Immunity: Neurotransmitters, Extracellular K ⁺ and T-Cell Function", Trends in Immunology, 22(1): 2-5, 2001.			
	9	Levite "Neuropeptides, by Direct Interaction With T Cells, Induce Cytokine Secretion and Break the Commitment to A Distinct T Helper Phenotype", Proc. Natl. Acad. Sci. USA, 95: 12544-12549, 1998.			
	10	Nakanishi et al. "Glutamate Receptors: Brain Function and Signal Transduction", Brain Research Reviews, 26: 230-235, 1998.			
	11	Yoles et al. "Protective Autoimmunity Is A Physiological Response to CNS Trauma", The Journal of Neuroscience, 21(11): 3740-3748, 2001.			
	12	Lombardi et al. "Characterization of Ionotropic Glutamate Receptors in Human Lymphocytes", British Journal of Pharmacology, 133: 936-944, 2001.			

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.